Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine
06 avr. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond mild intensity in 74% of...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
12 mars 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NDA filing for Breakthrough Therapy designated AXS-05 in MDD expected in 4Q 2020 NDA filing for AXS-07 in migraine expected in 4Q 2020 Topline results for STRIDE-1 Phase 3 trial of AXS-05 in TRD on...
Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer
05 mars 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
04 mars 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, March 12, 2020 at 8:00 AM Eastern Time NEW YORK, March 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
20 févr. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
30 déc. 2019 06h15 HE
|
Axsome Therapeutics, Inc.
Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p<0.001) and freedom from most bothersome symptom (p=0.002) at 2 hours, compared to placebo Demonstrated...
Axsome Therapeutics Added to NASDAQ Biotechnology Index
17 déc. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine
21 nov. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Company to host conference call on Monday, November 25 at 9:00 AM Eastern NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
07 nov. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...
Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019
29 oct. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, November 7, 2019 at 8:00 AM Eastern Time NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...